NCT05518903
- Conditions
- Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +10 more
- Locations
-
- Mayo Clinic in Rochester Rochester, Minnesota, United States
Clinical trial condition
Resectable Pancreatic Ductal Adenocarcinoma
Explore clinical trials studying Resectable Pancreatic Ductal Adenocarcinoma. Study availability and eligibility vary by location and protocol.
11 public trials
4 recruiting studies
Resectable Pancreatic Ductal Adenocarcinoma trial results
NCT04005690
- Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, +13 more
- Locations
-
- OHSU Knight Cancer Institute Portland, Oregon, United States
Recruiting
Using Tumour DNA and Proteins to Better Understand How Pancreatic Cancer Responds to Treatment
NCT06574620
- Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, +1 more
- Locations
-
- BC Cancer Vancouver, British Columbia, Canada
NCT06595160
- Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, +8 more
- Locations
-
- Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States
Not yet recruiting
Samuraciclib for the Treatment of Patients With Resectable, Borderline Resectable, or Locally Advanced Basal Pancreatic Cancer
NCT07645651
- Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
- Locations
-
- Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
Not yet recruiting
SMAD4 Tailored Neoadjuvant Therapy for the Treatment of Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma, SMART-PANC Trial
NCT07748611
- Conditions
- Borderline Resectable Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
- Locations
-
- Northwestern University Chicago, Illinois, United States
Enrolling by invitation
Recurrent Disease Detection After Resection of Pancreatic Adenocarcinoma Using a Standardized Surveillance Strategy
NCT04875325
- Conditions
- Recurrent Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
- Locations
-
- Radboud University Medical Center Nijmegen, Gelderland, Netherlands
- Maastricht UMC Maastricht, Limburg, Netherlands
- Catharina Ziekenhuis Eindhoven, North Brabant, Netherlands
- Amsterdam University Medical Center VUmc Amsterdam, North Holland, Netherlands
Active, not recruiting
A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients With Pancreatic Cancer
NCT05055323
- Conditions
- Digestive System Diseases, Digestive System Neoplasms, Endocrine Gland Neoplasms, +13 more
- Locations
-
- Thomas Jefferson University Philadelphia, Pennsylvania, United States
Active, not recruiting
NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer
NCT04484909
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Digestive System Diseases, Digestive System Neoplasms, +9 more
- Locations
-
- M D Anderson Cancer Center Houston, Texas, United States
NCT03970252
- Conditions
- Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma
- Locations
-
- UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States